© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
December 15, 2020
The primary objective of the study was to assess the benefit of cytoreductive nephrectomy relative to immunotherapy regimens utilizing checkpoint inhibitors.
December 08, 2020
Phase 1 data suggest the anti–PD-1 immune checkpoint inhibitor is safe and tolerable in the neoadjuvant setting for patients with nonmetastatic high-risk clear cell renal cell carcinoma.
December 07, 2020
No new safety signals were reported with the androgen receptor pathway inhibitor.
Patients undergoing pouch diversion reported significantly more regret than patients undergoing neobladder or ileal conduit.
December 05, 2020
Over half of patients who achieved a complete response to Jelmyto maintained that response at 12 months.
The in-depth interview covers the data that led to the NMIBC approval, outlines the appropriate patient population for pembrolizumab, and reviews side-effect management with the immune checkpoint inhibitor.
Researchers examined the prevalence of germline mutations, as well as clinicopathologic factors linked to an increased risk of carrying these mutations.
Clinical activity with MK-6482 was observed in both RCC and non-RCC lesions.
December 04, 2020
The algorithm was applied to 50 patients who underwent radical prostatectomy between 2008 and 2018.
Ten-year data showed high overall survival and recurrence-free survival rates with Mohs surgery in patients with localized penile cancer.